Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Erasca Inc. currently has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 3 distinct examiners, all of whom are located within 1 distinct art unit. ROMERO, KRISTEN WANG is identified as the busiest examiner, managing 1 pending action.
Despite the involvement of multiple examiners, the concentration within 1 distinct art unit suggests a unified procedural framework for the portfolio's prosecution. Practitioners can leverage this art unit consistency while tailoring their approach to the individual styles of the examiners. The even distribution of the 3 pending actions across the examiners indicates a broad but technically focused prosecution effort within the Biotechnology & Pharmaceuticals sector. This arrangement allows for a comparison of examiner behaviors within the same technical group. The presence of only 1 distinct art unit simplifies the technical oversight required for the pending office actions. Each of the 3 distinct examiners handles a single case, ensuring that no individual is overburdened with the company's current workload. This structure provides a balanced but technically unified prosecution landscape.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROMERO, KRISTEN WANG | 1 | 68.8% | +31.9% |
| ANDERSON, REBECCA L | 1 | 73.4% | +23.6% |
| KUCKLA, ANNA GRACE | 1 | 53.2% | +54.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18572399 | ERK1/2 AND KRAS G12C INHIBITORS COMBINATION THERAPY | ANDERSON, REBECCA L | 4d overdue |
| 18708947 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ROMERO, KRISTEN WANG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18572412 | SHP2 AND CDK4/6 INHIBITORS COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | KUCKLA, ANNA GRACE | 19d overdue |
| 18572399 | ERK1/2 AND KRAS G12C INHIBITORS COMBINATION THERAPY | ANDERSON, REBECCA L | 4d overdue |
| 18708947 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ROMERO, KRISTEN WANG | — |
| Art Unit | Apps |
|---|---|
| 1626 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18708947 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ROMERO, KRISTEN WANG | — | §102§112 | Non-Final OA | — | Pending | May 09, 2024 |
| 18572399 | ERK1/2 AND KRAS G12C INHIBITORS COMBINATION THERAPY | ANDERSON, REBECCA L | 1626 | §103§112Other | Non-Final OA | 4d overdue | Pending | Dec 20, 2023 |
| 18572412 | SHP2 AND CDK4/6 INHIBITORS COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | KUCKLA, ANNA GRACE | 1626 | §103Other | Non-Final OA | 19d overdue | Pending | Dec 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial